ArticleBMC cancer2025
KLC3 drives gastric cancer progression by stabilizing SLC2A5 to activate MAPK signaling and promote epithelial-mesenchymal transition.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Prognostic value of neuro-related genes in colorectal cancer and their potential implications for immunotherapy.Journal of Cancer · 2026Article
- Druggable Genome-Wide Mendelian Randomization Identifies Therapeutic Targets and DNA Methylation-Mediated Regulation in Urological Malignancies.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundGastric cancer (GC) is associated with poor prognosis due to its intricate molecular mechanisms that drive multiple malignant functions. While KLC3 has been found to be abnormally expressed in various tumors, its specific mechanistic role in GC remains largely unknown.
aimsThis study aimed to elucidate the functional role of KLC3 in GC and to investigate its involvement in regulating the MAPK signaling pathway via SLC2A5.
methodsThe expression of KLC3 was evaluated in GC tissues and cell lines. Functional assays (CCK8, colony formation, wound healing, Transwell) and an in vivo xenograft model were used to assess its role in proliferation, invasion, and migration. Transcriptome sequencing, co-immunoprecipitation, and rescue experiments were employed to uncover the underlying mechanisms.
resultsKLC3 was significantly upregulated in GC and associated with poor patient survival. Its knockdown suppressed GC cell growth, invasion, and migration in vitro and in vivo, attenuated EMT, and reduced SLC2A5 expression. Mechanistically, KLC3 interacts with SLC2A5, potentially regulating its membrane localization and stability, and thus activating the MAPK pathway. Crucially, overexpression of SLC2A5 rescued the inhibitory effects of KLC3 knockdown on the MAPK pathway and EMT.
conclusionThis study identifies KLC3 as a key oncoprotein that promotes GC progression by modulating the MAPK signaling pathway through a novel interaction with the fructose transporter SLC2A5. The KLC3-SLC2A5 axis may serve as a critical link between cellular motor machinery and metabolic reprogramming in cancer, presenting a promising therapeutic target for GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.